135 reports of this reaction
4.1% of all ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE reports
#2 most reported adverse reaction
DISEASE RECURRENCE is the #2 most commonly reported adverse reaction for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, manufactured by The Procter & Gamble Manufacturing Company. There are 135 FDA adverse event reports linking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE to DISEASE RECURRENCE. This represents approximately 4.1% of all 3,300 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE who experience disease recurrence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE RECURRENCE is moderately reported among ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE users, representing a notable but not dominant share of adverse events.
In addition to disease recurrence, the following adverse reactions have been reported for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE:
The following drugs have also been linked to disease recurrence in FDA adverse event reports:
DISEASE RECURRENCE has been reported as an adverse event in 135 FDA reports for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE RECURRENCE accounts for approximately 4.1% of all adverse event reports for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, making it one of the most commonly reported side effect.
If you experience disease recurrence while taking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.